In larger doses, the diabetes drug may increase height in children and adolescents.
The FDA has approved the FlexPro PenMate is intended for users of Norditropin, which is indicated for patients with growth hormone-related disorders, who prefer hidden needles during injection.
Ferring announced that the FDA has approved the name changes of its newly acquired products to be marketed as Zomacton (somatropin [rDNA origin]; formerly Tev-Tropin) for injection, and the needle-free delivery system as Zoma-Jet (formerly Tjet).
Researchers have discovered a single gene in a region of the X chromosome that may cause excessive growth in children.
Young female athletes my experience endocrine disorders, including menstrual problems and difficulty with bone mass, due to intense training.
New study doubles the number of gene regions linked to height.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Improving Vascular Function in Pediatric T1D With Metformin
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation